from
Datamonitor Premium Research Reports192 page (60455 word) report
published Jul 29, 2003
Price
$15,200.00 available for immediate download
Report Overview
Search Inside
About
Datamonitor Premium Research R...
...Despite facing adversity in the past year surrounding the CV side-effect profile of Vioxx and the delayed launch of Arcoxia, Merck will remain a strong competitor for Pfizer/Pharmacia in the future and the COX-II inhibitor class will continue to flourish to 2011. The alleviation of Enbrel s supply shortage in 2003 will enable Amgen to regain its lead over J&J s Remicade although Humira is presenting formidable competition for both of these market leaders; Enbrel sales were $802m in 2002, representing growth of 5% from 2001 sales, while Remicade sales were $1,513m, representing year-on-year growth of 78%. ...
|
| Industry(ies): | Healthcare, Immune Disorders and Inflammation
|
| Free Sample: |
Click Here to Download
|
| Format: | | PDF |  |
|
Datamonitor is a premium business information company specializing in industry analysis. Datamonitor's industry research addresses complex strategic issues by providing unbiased expert analysis and in-depth forecasts across the Automotive, Consumer, Energy, Financial Services, Healthcare & Technology sectors.
